Symbols

TXMD

Therapeuticsmd

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TXMD

Therapeuticsmd, Inc.

A company that develops branded prescription, generic prescription and over-the-counter produts for women

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

10/09/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.therapeuticsmd.com

Security Type

Common stock

Office address

951 Yamato Road, Suite 220, Boca Raton, Florida 33431

Business

Introduction

Therapeuticsmd, Inc., was incorporated in Utah in 1907 as Croff Mining Company, subsequently renamed Croff Oil Company in 1952 and Croff Enterprises, Inc., in 1996. Is a women's healthcare products company focused on creating and commercializing products specifically for women. The company currently manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and cosmetics. The company is currently focused on conducting clinical trials required for regulatory approval and commercialization of advanced hormone therapies (HT), drug products designed to relieve symptoms and reduce health risks associated with menopause-related hormone deficiency, including hot flashes, osteoporosis and vaginal dryness. The company is developing these proposed hormone therapy products, which contain estradiol and progesterone alone or in combination, with the aim of providing equivalent efficacy at lower doses, thereby enhancing side effect characteristics compared to competing products. Therapeuticsmd, Inc., has received acceptance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct clinical trials on three proposed products and intends to commence clinical trials on two of them.

Company Financials

EPS

TXMD has released its 2025 Q1 earnings. EPS was reported at -0.06, versus the expected 0, missing expectations. The chart below visualizes how TXMD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TXMD has released its 2025 Q1 earnings report, with revenue of 393.00K, reflecting a YoY change of 25.56%, and net profit of -653.00K, showing a YoY change of 11.04%. The Sankey diagram below clearly presents TXMD's revenue sources and cost distribution.